XILIO THERAPEUTICS, INC. Records Net Loss of $19.4 Million in Q2 2023

XILIO THERAPEUTICS, INC.(XLO), a leading biopharmaceutical company, released its financial results for the second quarter of 2023, reporting a net loss of $19.4 million. The company generated revenue amounting to $20.1 million during this period, showcasing its ongoing commitment to advancing therapeutic solutions.**

XILIO THERAPEUTICS, INC. recently disclosed its Condensed Consolidated Balance Sheets and financial statements for the second quarter of 2023. The company's performance is dissected below in terms of net income/loss and revenue.

Net Loss of $19.4 Million in Q2 2023

During the three months ended June 30, 2023, XILIO THERAPEUTICS, INC. reported a net loss of $19.4 million. This figure reflects the company's operating expenses, research and development costs, and general administrative expenditures. The net loss per share, both basic and diluted, was calculated at $0.70 for this quarter. The weighted average number of common shares outstanding during this period was approximately 27.5 million.